Submission Details
| 510(k) Number | K233293 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | September 29, 2023 |
| Decision Date | January 16, 2024 |
| Days to Decision | 109 days |
| Submission Type | Traditional |
| Review Panel | Neurology (NE) |
| Summary | Summary PDF |
K233293 is an FDA 510(k) clearance for the Generation 2.0 Monarch external Trigeminal Nerve Stimulation (eTNS) System?, a Transcutaneous Nerve Stimulator For Adhd (Class II — Special Controls, product code QGL), submitted by Neurosigma, Inc. (Los Angeles, US). The FDA issued a Cleared decision on January 16, 2024, 109 days after receiving the submission on September 29, 2023. This device falls under the Neurology review panel. Regulated under 21 CFR 882.5898.
| 510(k) Number | K233293 FDA.gov |
| FDA Decision | Cleared SESE |
| Date Received | September 29, 2023 |
| Decision Date | January 16, 2024 |
| Days to Decision | 109 days |
| Submission Type | Traditional |
| Review Panel | Neurology (NE) |
| Summary | Summary PDF |
| Product Code | QGL — Transcutaneous Nerve Stimulator For Adhd |
| Device Class | Class II — Special Controls |
| CFR Regulation | 21 CFR 882.5898 |
| Definition | A Transcutaneous Electrical Nerve Stimulator For Attention Deficit Hyperactivity Disorder (adhd) Is A Prescription Device That Stimulates Transcutaneously Or Percutaneously Through Electrodes Placed On The Forehead. |